Related Experiment Video

Updated: Jun 24, 2026

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

Ischemia-reperfusion-inducible protein modulates cell sensitivity to anticancer drugs by regulating activity of

Olga Prokopenko1, Oleg Mirochnitchenko

  • 1Department of Biochemistry, Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.

American Journal of Physiology. Cell Physiology
|March 13, 2009
PubMed

Insights

Human ischemia-reperfusion-inducible protein (hIRIP) regulates cellular drug sensitivity by inhibiting efflux transporters like P-glycoprotein. hIRIP affects P-glycoprotein processing and degradation, impacting multidrug resistance mechanisms.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • Human ischemia-reperfusion-inducible protein (hIRIP), also known as hYrdC, is part of the SUA5/YrdC/YciO protein family.
  • hIRIP influences the activity of various cellular transporters.
  • Overexpression of hIRIP affects cellular sensitivity to anticancer drugs.

Purpose of the Study:

  • To investigate the detailed effect of hIRIP on cellular sensitivity to doxorubicin.
  • To elucidate the mechanism by which hIRIP influences drug efflux.
  • To identify the specific transporters targeted by hIRIP.

Main Methods:

  • Cell-based assays to assess drug sensitivity.
  • Analysis of protein processing and degradation pathways.
  • Co-immunoprecipitation to study protein-protein interactions.

Main Results:

  • hIRIP inhibits doxorubicin efflux from cells.
  • P-glycoprotein was identified as a key target transporter affected by hIRIP.
  • hIRIP promotes P-glycoprotein degradation without affecting its biosynthesis.
  • hIRIP expression levels modulate the interaction between P-glycoprotein and COP-alpha.

Conclusions:

  • hIRIP plays a regulatory role in the function of efflux transporters, particularly P-glycoprotein.
  • hIRIP influences multidrug resistance by affecting P-glycoprotein processing and stability.
  • These findings provide insights into novel therapeutic strategies targeting drug efflux mechanisms in cancer treatment.

More Related Videos

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation08:05

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on: June 8, 2018

Related Concept Videos

Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...